Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Jeroen Bosch Ziekenhuis | OTHER |
| Elisabeth-TweeSteden Ziekenhuis | OTHER |
| Catharina Ziekenhuis Eindhoven | OTHER |
| Bernhoven Hospital |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine whether 40 mg octreotide long-acting release intramuscular every 28 days is effective in the treatment of patients with refractory anemia due to gastrointestinal angiodysplasias. We hypothesize that octreotide is effective in reducing the transfusion requirements (consisting of red blood cell transfusions and intravenous iron infusions) of patients with angiodysplasia-related anemia.
Rationale: Gastrointestinal angiodysplasias are a common source of intractable small bowel bleeding, especially in older patients. Endoscopic ablation of angiodysplasias has limited efficacy and rebleeding rates are substantial. Recurrent bleeding results in refractory anemia which is managed with blood transfusions and/or iron infusions. Transfusion dependency reduces quality of life and is associated with substantial cardiovascular morbidity and mortality. Small cohort studies suggest a beneficial effect of octreotide in bleeding angiodysplasias, but evidence from rigorous, well-controlled studies are lacking.
Objective: To assess the efficacy of octreotide in reducing the transfusion requirements (consisting of blood transfusions and iron infusions) of patients with refractory anemia due to gastrointestinal angiodysplasias despite endoscopic intervention.
Study design: Multicenter, randomized, open-label intervention study.
Study population: Patients aged 18 years or older with transfusion-dependent anemia due to endoscopically confirmed angiodysplasias. Transfusion units consist of iron infusions (of 500 milligrams [mg]) and red blood cell (RBC) transfusions. At least one endoscopic attempt to treat the angiodysplasias needs to be recorded unless contra-indications are present. Patients with liver cirrhosis Child-Pugh C or liver failure, uncontrolled diabetes mellitus (defined by a glycated hemoglobin >64 mmol/mL), symptomatic cholecystolithiasis, and pregnant or nursing women, are regarded as ineligible because of the pharmacological profile of octreotide. Patients with hereditary hemorrhagic diseases or hematological disorders on active treatment, other alternative causes of gastrointestinal bleeding, presence of left ventricular assist devices, as well as patients with cancer under active treatment, and those with a life expectancy <1 year are excluded from enrolment
Intervention: Patients will be randomized (1:1) into two groups. The intervention group receives 40 mg octreotide long-acting release (Sandostatin LAR) every 28 days for a total period of 52 weeks as an adjunct to standard of care. The control group receives standard of care along. The last follow-up visit is in week 60.
Main study parameters/endpoints: The primary endpoint is defined as the mean difference in blood (RBC transfusions per 500 ml or packed cells) and parenteral iron (IV iron infusions per 500 mg) requirements between the intervention and control group, corrected for baseline transfusion requirements and follow-up time.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Octreotide | Active Comparator | Drug: Sandostatin LAR Sandostatin LAR 40 mg will be administered once every 4 weeks as a intramuscular injection |
|
| Standard of care | No Intervention | Patients receive standard of care without a placebo. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Octreotide | Drug | Two injections of 20 mg will be given monthly. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Difference in blood and parenteral iron requirements (transfusion units) | The mean difference in blood (RBC transfusions per 500 ml or packed cells) and parenteral iron (IV iron infusions per 500 mg) requirements between the intervention and standard of care arm, corrected for baseline transfusion requirements and follow-up time. | Study year (52 weeks) |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion with a good treatment response | The proportion of patients in both groups that experienced a ≥50% (defined as a good response) and 100% (defined as a full response) reduction in the number of transfusion units received during the study year compared to baseline | During the study year (52 weeks) compared to the year (52 weeks) before randomization |
| Measure | Description | Time Frame |
|---|---|---|
| Subgroup analyses on blood transfusion dependency | Analyses include all patients that required at least one red blood cell transfusion (per 500 ml or packed cells) in the year before randomization (52 weeks). | Study year (52 weeks) |
| Subgroup analyses on use of antithrombotics |
Inclusion criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Joost Drenth, MD. PhD | Radboud University Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Gelre Hospital | Apeldoorn | Gelderland | 7334 DZ | Netherlands | ||
| Radboud University Medical Center (Radboudumc) |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38158089 | Derived | Goltstein LCMJ, Grooteman KV, Bernts LHP, Scheffer RCH, Laheij RJF, Gilissen LPL, Schrauwen RWM, Talstra NC, Zuur AT, Braat H, Hadithi M, Brouwer JT, Nagengast WB, Oort FA, Tenthof van Noorden J, Kievit W, van Geenen EJM, Drenth JPH. Standard of Care Versus Octreotide in Angiodysplasia-Related Bleeding (the OCEAN Study): A Multicenter Randomized Controlled Trial. Gastroenterology. 2024 Apr;166(4):690-703. doi: 10.1053/j.gastro.2023.12.020. Epub 2023 Dec 28. | |
| 27619827 |
| Label | URL |
|---|---|
| Announcement of research project in the "Nederlands Tijdschrift voor Geneeskunde" | View source |
| ID | Type | URL | Comment |
|---|---|---|---|
| 27619827 | Study Protocol | View IPD |
Deidentified individual participant data and a data dictionary defining each field in the set will be available, upon reasonable request to Lia Goltstein and subjected to an appropriate data sharing agreement.
Not provided
Data sharing agreement
Not provided
Not provided
| OTHER |
| Tjongerschans hospital | UNKNOWN |
| Gelre Hospitals | OTHER |
| Maasstad Hospital | OTHER |
| Reinier de Graaf Groep | OTHER |
| University Medical Center Groningen | OTHER |
| Rijnstate Hospital | OTHER |
| St. Antonius Hospital | OTHER |
Multicenter, open-label, randomized, parallel-group, superiority study to compare the efficacy of 40 mg octreotide long-acting release intramuscular every 28 days in addition to standard of care versus standard of care alone in patients with refractory anemia due to gastrointestinal bleeding from angiodysplasias.
Not provided
Not provided
The trial was blinded for the outcome adjudication committee but not for patients or attending physicians.
| Use of concomitant care | The proportion of patients in both groups that required concomitant care. Concomitant care consists of application of APC, discontinuation of antithrombotics, use of tranexamic acid, and starting octreotide in the control group. | Study year (52 weeks) |
| Difference in endoscopic procedures | The mean difference in endoscopic procedures between both groups. | Study year (52 weeks) |
| Difference in bleeding episodes | The mean difference in bleeding episodes between both groups. A bleeding episode is defined as each non-contiguous episode in which hospital care is sought for anemia. | Study year (52 weeks) |
| Difference in healthcare utilization | The mean difference in healthcare utilization between both groups. Healthcare utilization consists of hospital admissions, ambulatory care, and emergency care. | Study year (52 weeks) |
| Difference in hemoglobin levels | The mean difference in serum hemoglobin levels (mmol/L) between both groups. | Study year (52 weeks) |
| Difference in ferritin levels | The mean difference in serum ferritin levels (ug/L) between both groups. | Study year (52 weeks) |
| Difference in fatigue levels | The mean difference in fatigue levels between both groups. Fatigue is a patient-reported outcome measure (PROM), measured by the Multidimensional Fatigue Inventory (MFI-20), which covers five dimensions of fatigue affect and -tolerability. MFI-20 scores range from 20 (best) to 100 (worst). | Study year (52 weeks) |
| Difference in quality of life | The mean difference in quality of life between both groups. Quality of life is a patient-reported outcome measure (PROM), measured by the Short Form Health Survey (SF-36), which uses eight subdomains to evaluate physical- and mental health. SF-36 scores range from 0 (worst) to 100 (best). | Study year (52 weeks) |
| Difference in adverse events | The proportion of patients in both groups that experienced at least one adverse event (AE). | Study year (52 weeks) |
| Difference in serious adverse events | The proportion of patients in both groups that experienced at least one serious adverse event (SAE). | Study year (52 weeks) |
| Difference in mortality | The proportion of patients in both groups that died during the study. | Study year (52 weeks) |
Analyses include all patients that required at least one form of antithrombotics in the year before randomization (52 weeks). |
| Study year (52 weeks) |
| Nijmegen |
| Gelderland |
| 6525GA |
| Netherlands |
| Jeroen Bosch Hospital | 's-Hertogenbosch | North Brabant | 5200 ME | Netherlands |
| Catharina Hospital | Eindhoven | North Brabant | 5623 EJ | Netherlands |
| Elisabeth-TweeSteden Hospital | Tilburg | North Brabant | 5022 GC | Netherlands |
| Reinier de Graaf Gasthuis | Delft | South Holland | 2625 AD | Netherlands |
| St. Antonius Hospital | Nieuwegein | Utrecht | 3430 EM | Netherlands |
| Rijnstate Hospital | Arnhem | 6815AD | Netherlands |
| University Medical Center Groningen (UMCG) | Groningen | 9713GZ | Netherlands |
| Tjongerschans Hospital | Heerenveen | 8441 PW | Netherlands |
| Maasstad Hospital | Rotterdam | Netherlands |
| Bernhoven Hospital | Uden | 5406 PT | Netherlands |
| Derived |
| Grooteman KV, van Geenen EJ, Drenth JP. Multicentre, open-label, randomised, parallel-group, superiority study to compare the efficacy of octreotide therapy 40 mg monthly versus standard of care in patients with refractory anaemia due to gastrointestinal bleeding from small bowel angiodysplasias: a protocol of the OCEAN trial. BMJ Open. 2016 Sep 12;6(9):e011442. doi: 10.1136/bmjopen-2016-011442. |
| ID | Term |
|---|---|
| D016888 | Angiodysplasia |
| D054079 | Vascular Malformations |
| D006471 | Gastrointestinal Hemorrhage |
| D000740 | Anemia |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D018376 | Cardiovascular Abnormalities |
| D000013 | Congenital Abnormalities |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |
| D006470 | Hemorrhage |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D015282 | Octreotide |
| ID | Term |
|---|---|
| D010456 | Peptides, Cyclic |
| D047028 | Macrocyclic Compounds |
| D011083 | Polycyclic Compounds |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |
Not provided
Not provided